首页> 美国卫生研究院文献>Arthritis Research >Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis
【2h】

Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis

机译:雷洛昔芬减少类风湿关节炎患者滑膜细胞的尿激酶型纤溶酶原激活剂依赖性增殖

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Extracellular fibrinolysis, controlled by the membrane-bound fibrinolytic system, is involved in cartilage damage and rheumatoid arthritis (RA) synovitis. Estrogen status and metabolism seem to be impaired in RA, and synoviocytes show receptors for estrogens. Our aims in this study were to evaluate in healthy and RA synoviocytes the effects of Raloxifene (RAL), a selective estrogen receptor modulator (SERM), on: proliferation; the components of the fibrinolytic system; and chemoinvasion. The effects of RAL were studied in vitro on synoviocytes from four RA patients and four controls. Proliferation was evaluated as cell number increase, and synoviocytes were treated with 0.5 μM and 1 μM RAL with and without urokinase-plasminogen activator (u-PA) and anti-u-PA/anti-u-PA receptor (u-PAR) antibodies. Fibrinolytic system components (u-PA, u-PAR and plasminogen activator inhibitor (PAI)-1) were assayed by ELISA with cells treated with 0.5 μM and 1 μM RAL for 48 h. u-PA activity was evaluated by zymography and a direct fibrinolytic assay. U-PAR/cell and its saturation were studied by radioiodination of u-PA and a u-PA binding assay. Chemoinvasion was measured using the Boyden chamber invasion assay. u-PA induced proliferation of RA synoviocytes was blocked by RAL (p < 0.05) and antagonized by antibodies alone. The inhibitory effect of RAL was not additive with u-PA/u-PAR antagonism. RA synoviocytes treated with RAL showed, compared to basal, higher levels of PAI-1 (10.75 ± 0.26 versus 5.5 ± 0.1 μg/106 cells, respectively; p < 0.01), lower levels of u-PA (1.04 ± 0.05 versus 3.1 ± 0.4 ng/106 cells, respectively; p < 0.001), and lower levels of u-PAR (11.28 ± 0.22 versus 23.6 ± 0.1 ng/106 cells, respectively; p < 0.001). RAL also significantly inhibited u-PA-induced migration. Similar effects were also shown, at least partially, in controls. RAL exerts anti-proliferative and anti-invasive effects on synoviocytes, mainly modulating u-PAR and, to a lesser extent, u-PA and PAI-1 levels, and inhibiting cell migration and proliferation.
机译:细胞外纤维蛋白溶解受膜结合纤维蛋白溶解系统的控制,参与软骨损伤和类风湿关节炎(RA)滑膜炎。 RA中雌激素的状态和代谢似乎受到损害,滑膜细胞显示出雌激素的受体。我们在这项研究中的目的是评估健康和RA滑膜细胞中雷洛昔芬(RAL)(一种选择性雌激素受体调节剂(SERM))对以下细胞的作用:纤溶系统的组成部分;和化学入侵。在体外研究了RAL对来自4名RA患者和4名对照的滑膜细胞的影响。评估增殖随着细胞数量的增加,滑膜细胞用0.5μM和1μMRAL处理,有和没有尿激酶纤溶酶原激活剂(u-PA)和抗u-PA /抗u-PA受体(u-PAR)抗体。纤溶系统成分(u-PA,u-PAR和纤溶酶原激活物抑制剂(PAI)-1)通过ELISA分析,细胞经0.5μM和1μMRAL处理48小时。 u-PA活性通过酶谱和直接纤溶测定法进行评估。通过u-PA的放射性碘化和u-PA结合测定研究了U-PAR /细胞及其饱和度。使用博伊登室侵袭测定法测量化学浸润。 u-PA诱导的RA滑膜细胞增殖被RAL阻断(p <0.05),并被单独的抗体拮抗。 RAL的抑制作用与u-PA / u-PAR拮抗作用无关。与基础相比,经RAL处理的RA滑膜细胞显示较高水平的PAI-1(分别为10.75±0.26和5.5±0.1μg/ 10 6 sups细胞; p <0.01),较低的u- PA(分别为1.04±0.05与3.1±0.4 ng / 10 6 细胞; p <0.001)和较低水平的u-PAR(11.28±0.22与23.6±0.1 ng / 10 分别为6 个单元格; p <0.001)。 RAL也显着抑制u-PA诱导的迁移。在对照组中也显示出至少部分相似的效果。 RAL对滑膜细胞具有抗增殖和抗侵袭作用,主要调节u-PAR,并在较小程度上调节u-PA和PAI-1水平,并抑制细胞迁移和增殖。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号